Beyond conventional immune checkpoints: the LILRB axis as a dual regulator of tumor and immune cell states

Journal of Experimental & Clinical Cancer Research · Published 2026-08-01 · DOI 10.1186/s13046-026-03796-2

Free full text

Authors (6)

Alessandro Scagliotti, Ivan Depetro, Giorgia Tiberi, Paula Ariadna Diez-Villegas, Ermes Candiello, Paola Cappello

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Scagliotti, A., Depetro, I., Tiberi, G., et al. (2026). Beyond conventional immune checkpoints: the LILRB axis as a dual regulator of tumor and immune cell states. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03796-2

Related articles

• Transforming tumor microenvironments: nanotechnology and gene therapy in cellular signaling and epigenetic insight into chemo-resistance · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Targeting the lipid desaturation network in cancer: from metabolic plasticity to precision therapeutics · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Inhibition of 5’-tiRNAGly restores anti-PD-1 immunotherapy efficacy via DLST-mediated OGDHL succinylation in gastric cancer · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Bi-directional regulation between NAD/NAMPT and IFN-γ/PD-L1 axes via BRD4/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Soulangianolide A targets FAM120A to disrupt SREBP1-driven lipid metabolic reprogramming and suppress clear cell renal cell carcinoma · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Extracellular vesicle–mediated GALNT1/RPRD1A glycosylation axis drives immune escape and peritoneal metastasis in gastric cancer · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Targeting immunoglobulin superfamily member 9 (IGSF9) to overcome acute myeloid leukemia resistance to CAR-T therapy · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• ASCL2-mediated macrophage-myofibroblast transition generates immunosuppressive CAF_7 in NSCLC bone metastases · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Cancer therapy resistance converges on immune evasion: a unified framework from immunotherapy to targeted, endocrine, and DNA repair pathways · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• ZEB1 integrates stemness, differentiation blockade and immune suppression to orchestrate osteosarcoma aggressiveness · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal